Placebo | l-arginine | Difference in changes between l-arginine and placebo1-152 | |
---|---|---|---|
FEV1 (% predicted) | |||
Baseline | 92.8 (85.8 to 99.9) | 96.6 (87.9 to 105.4) | |
30 min | 95.1 (88.3 to 102.0) | 95.3 (88.1 to 102.6) | −3.6 (−7.4 to 0.2) |
60 min | 93.4 (85.8 to 100.9) | 93.3 (85.3 to 101.3) | −3.7 (−8.2 to 0.8) |
90 min | 95.2 (87.9 to 102.5) | 94.0 (87.2 to 100.8) | −5.0 (−9.3 to −0.8)1-150 |
Exhaled NO (ppb) | |||
Baseline | 17.4 (12.5 to 22.3) | 19.9 (13.0 to 26.8) | |
30 min | 19.0 (13.9 to 24.2) | 21.8 (14.8 to 28.7) | 0.3 (−2.3 to 2.8) |
60 min | 18.0 (14.0 to 22.0) | 21.6 (14.6 to 28.5) | 1.1 (−2.9 to 5.1) |
90 min | 19.5 (15.5 to 23.5) | 22.0 (15.3 to 28.5) | −0.1 (−3.2 to 3.1) |
PC20 histamine (mg/ml)1-151 | 0.41 (0.20 to 0.82) | 0.46 (0.24 to 0.86) | |
DRS (% fall/μmol)1-151 | 10.8 (4.8 to 24.5) | 7.9 (3.4 to 18.2)1-150 |
FEV1 = forced expiratory volume in one second; ppb = parts per billion; PC20 = provocative concentration causing a 20% fall from baseline FEV1, DRS = dose-response slope.
↵1-150 p<0.05.
↵1-151 Data are geometric mean (95% confidence interval).
↵1-152 Difference in changes from baseline values in FEV1 and exhaled NO between l-arginine and placebo pretreatment.